Sample size: how many participants do I need in my research?
Martínez-Mesa J, González-Chica DA, Bastos JL, Bonamigo RR, Duquia RP
Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region
Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos Alberto Sampaio-Filho, Aknar Calabrich, Carlos H. Barrios J Clin Oncol 31, 2013 (suppl; abstr e12510) Full link: https://meetinglibrary.asco.org/record/96361/abstract
A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane
(LACOG 0801).Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowsky H, Neron Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capo A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH.San Antonio Breast Cancer Symposium 2013; Abstract P4-12-26 Full link: https://cancerres.aacrjournals.org/content/73/24_Supplement/P4-12-26
Inequities in Pap smear screening for cervical cancer between Brazilian urban and rural populations.
Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos Alberto Sampaio-Filho, Aknar Calabrich, Carlos H. BarriosJ Clin Oncol 31, 2013 (suppl; abstr e12510) Full link: https://meetinglibrary.asco.org/record/82753/abstract
Breast cancer in Brazil: present status and future goals.
Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE.
A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801 / EGF111792).
Henry Gomez, Silvia P. Neciosup, Celia Tosello, Patricia Xavier, Yeni Neron do Nascimento, Marcelo Fanelli, Gustavo Ismael, Jose Bines, Carlos Sampaio, Guillermo Luis Lerzo, Adolfo Miguel Capo, Max S. Mano, Luis Fein, Gustavo Werutsky, Carlos H. Barrios
A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis
(GLICO-0801 / EGF111792).Henry Leonidas Gomez, Silvia P. Neciosup, Celia Tosello, Patricia Xavier, Yeni Neron do Nascimento, Marcelo Fanelli, Gustavo Ismael, Jose Bines, Carlos Sampaio, Guillermo Luis Lerzo, Adolfo Miguel Capo, Max S. Mano, Luis Fein, Gustavo Werutsky, Carlos H. BarriosJ Clin Oncol 30, 2012 (suppl; abstr e11087) Full link: https://meetinglibrary.asco.org/record/73652/abstract